Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sialic Acid Deposition Impairs the Utility of AAV9, but Not Peptide-modified AAVs for Brain Gene Therapy in a Mouse Model of Lysosomal Storage Disease

15 May 2012

Abstract excerpt

Recombinant vector systems have been recently identified that when delivered systemically can transduce neurons, glia, and endothelia in the central nervous system (CNS), providing an opportunity to develop therapies for diseases affecting the brain without performing direct intracranial injections. Vector systems based on adeno-associated virus (AAV) include AAV serotype 9 (AAV9) and AAVs that have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to RNA Interference and Gene Delivery
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22588273
DOI: 10.1038/mt.2012.100

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sialic Acid Deposition Impairs the Utility of AAV9, but Not Peptide-modified AAVs for Brain Gene Therapy in a Mouse Model of Lysosomal Storage DiseasePMID 22588273Read ↗

Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors.Semantic proximity Read ↗

Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy.Semantic proximity Read ↗

Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brainSemantic proximity Read ↗

Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID.Semantic proximity Read ↗

In Vivo Gene Therapy for Mucopolysaccharidosis Type III (Sanfilippo Syndrome): A New Treatment HorizonSemantic proximity Read ↗

Systemic AAV9 gene transfer in adult GM1 gangliosidosis mice reduces lysosomal storage in CNS and extends lifespanSemantic proximity Read ↗

AAV-mediated gene therapy for SialidosisSemantic proximity Read ↗

Adeno-associated viral vector serotype 9–based gene therapy for Niemann-Pick disease type ASemantic proximity Read ↗

Liver Production of Sulfamidase Reverses Peripheral and Ameliorates CNS Pathology in Mucopolysaccharidosis IIIA MiceSemantic proximity Read ↗

Reversal of Pathology in the Entire Brain of Mucopolysaccharidosis Type VII Mice after Lentivirus-Mediated Gene TransferSemantic proximity Read ↗

Targeting the Root Cause of Mucopolysaccharidosis IIIA with a New scAAV9 Gene Replacement VectorSemantic proximity Read ↗

Preferred transduction with AAV8 and AAV9 via thalamic administration in the MPS IIIB model: A comparison of four rAAV serotypesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.